These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

898 related articles for article (PubMed ID: 12477372)

  • 1. Terbinafine: a review of its use in onychomycosis in adults.
    Darkes MJ; Scott LJ; Goa KL
    Am J Clin Dermatol; 2003; 4(1):39-65. PubMed ID: 12477372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States.
    Gupta AK
    J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S81-95. PubMed ID: 11051137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes.
    Gupta AK; Gregurek-Novak T
    Dermatology; 2001; 202(3):235-8. PubMed ID: 11385230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails. A US analysis.
    Gupta AK
    Pharmacoeconomics; 1998 Feb; 13(2):243-56. PubMed ID: 10178650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of continuous terbinafine compared with intermittent itraconazole in the treatment of dermatophyte toenail onychomycosis: an analysis of based on results from the L.I.ON. study. Lamisil versus Itraconazole in Onychomycosis.
    Jansen R; Redekop WK; Rutten FF
    Pharmacoeconomics; 2001; 19(4):401-10. PubMed ID: 11383756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day.
    De Backer M; De Vroey C; Lesaffre E; Scheys I; De Keyser P
    J Am Acad Dermatol; 1998 May; 38(5 Pt 3):S57-63. PubMed ID: 9594939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly.
    Gupta AK; Konnikov N; Lynde CW
    J Am Acad Dermatol; 2001 Mar; 44(3):479-84. PubMed ID: 11209118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis.
    Gupta AK; Lynde CW; Konnikov N
    J Am Acad Dermatol; 2001 Mar; 44(3):485-91. PubMed ID: 11209119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral antifungal medication for toenail onychomycosis.
    Kreijkamp-Kaspers S; Hawke K; Guo L; Kerin G; Bell-Syer SE; Magin P; Bell-Syer SV; van Driel ML
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD010031. PubMed ID: 28707751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of dermatophyte toenail onychomycosis in the United States. A pharmacoeconomic analysis.
    Gupta AK
    J Am Podiatr Med Assoc; 2002 May; 92(5):272-86. PubMed ID: 12015408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Terbinafine. An update of its use in superficial mycoses.
    McClellan KJ; Wiseman LR; Markham A
    Drugs; 1999 Jul; 58(1):179-202. PubMed ID: 10439936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model.
    Marchetti A; Piech CT; McGhan WF; Neugut AI; Smith BT
    Clin Ther; 1996; 18(4):757-77; discussion 702. PubMed ID: 8879902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg/day vs. itraconazole 200 mg/day--a double-blind comparative trial.
    De Backer M; De Keyser P; De Vroey C; Lesaffre E
    Br J Dermatol; 1996 Jun; 134 Suppl 46():16-7: discussion 38. PubMed ID: 8763462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis.
    Arca E; Taştan HB; Akar A; Kurumlu Z; Gür AR
    J Dermatolog Treat; 2002 Mar; 13(1):3-9. PubMed ID: 12006131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of antifungal agents in onychomycoses.
    Debruyne D; Coquerel A
    Clin Pharmacokinet; 2001; 40(6):441-72. PubMed ID: 11475469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis.
    Gupta AK; Ryder JE; Johnson AM
    Br J Dermatol; 2004 Mar; 150(3):537-44. PubMed ID: 15030339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of oral terbinafine (Lamisil) compared with oral fluconazole (Diflucan) in the treatment of patients with toenail onychomycosis.
    Salo H; Pekurinen M
    Pharmacoeconomics; 2002; 20(5):319-24. PubMed ID: 11994041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections.
    Haria M; Bryson HM; Goa KL
    Drugs; 1996 Apr; 51(4):585-620. PubMed ID: 8706596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cost/efficacy analysis of oral antifungals indicated for the treatment of onychomycosis: griseofulvin, itraconazole, and terbinafine.
    Angello JT; Voytovich RM; Jan SA
    Am J Manag Care; 1997 Mar; 3(3):443-50. PubMed ID: 10173095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus.
    Gupta AK; Gover MD; Lynde CW
    J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1188-93. PubMed ID: 17062029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.